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Summary The molecular cytogenetic techniques of comparative genomic hybridization (CGH) and reverse in situ hybridization (REVISH)
allow the entire genomes of tumours to be screened for genetic changes without the requirement for specific probes or markers. In order to
define the ability of REVISH to detect and map regions of amplification associated with drug resistance, we investigated a panel of cell lines
selected for resistance to doxorubicin and intrinsic sensitivity to topoisomerase 11-inhibitory drugs. We have defined a modified REVISH
protocol, which involves double hybridizations with genomic DNA from the test cell lines and chromosome-specific whole chromosome paints
to identify the chromosomes to which the amplicons localize. Sites of amplification are then mapped by fractional length measurements
(Flpter), using published genome databases. Our findings show that amplification of the topoisomerase lla gene is readily detected and
mapped, as is amplification of the MDR and MRP loci. Interestingly, REVISH detected a new amplicon in the doxorubicin-resistant lung
cancer cell line, GLC4-ADR, which mapped to chromosome 1q. REVISH is therefore ideally suited to characterize genetic changes specific
for drug resistance within a background of genetic anomalies associated with tumour progression.
Keywords: molecular cytogenetics; fluorescence in situ hybridization; chromosome painting; drug resistance; gene amplification;
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Many tumours respond to a range of cytotoxic agents. However,
resistance often develops (van der Zee et al, 1995; Harrison,
1995). Understanding the mechanisms of resistance may provide
new therapeutic options (Kastan et al, 1995; FroelichAmmon and
Osheroff, 1995). At the cellular level, a number of resistance
mechanisms can potentially operate. These mechanisms include
drug efflux via membrane pumps, such as p-glycoprotein or
multidrug resistance protein (MRP), drug metabolism, including
inactivation or failure to activate a prodrug, an alteration in abun-
dance of the target protein, for example topoisomerase II (topoll)
enzyme, mutation of target protein and inactivation of pathways
leading to cell death, such as apoptotic signalling (Booser and
Hortobagyi, 1994; Harrison, 1995; Kastan et al, 1995; van der Zee
et al, 1995). It is likely that in any one particular tumour, response
to therapy is dependent on concurrent expression of multiple
mechanisms. Even for extensively studied drugs, such as etopo-
side, which is a known topoll inhibitor, resistance is a complex
issue (Su et al, 1992; Takano et al, 1992; Booser and Hortobagyi,
1994; Chen and Liu, 1994; Pommier et al, 1994; Sinha, 1995). The
recent association of reduced kinesin expression with etoposide
resistance, as identified by a genetic suppressor element approach,
highlights the usefulness and requirement for new approaches to
define potential components of the drug resistance repertoire
(Gudkov et al, 1994; Roninson et al, 1995).
A major drawback to many ofthe conventional approaches used
to investigate drug resistance mechanisms is that some prior infor-
mation orguesswork on the changes that have occurred is required,
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thus necessitating separate reagents to screen each possible change.
When analysing genetic changes for example, screening is limited
to the use of gene- or region-specific probes. Recently, the molec-
ular cytogenetic techniques of reverse in situ hybridization
(REVISH) and its more advanced relative, comparative genomic
hybridization (CGH), have been developed for the rapid global
detection and mapping of genetic imbalances in tumour genomes
(Kallioniemi et al, 1992, 1993; Joos et al, 1993; Houldsworth and
Chaganti, 1994; Lichter et al, 1995; Mitelman, 1995; Van Ommen
et al, 1995). In REVISH, genomic DNA from the tumour is used as
a complex probe and hybridized to normal metaphase chromo-
somes (Mitelman, 1995). Genomic sequences amplified in the
tumour are then detected as an increased intensity of signal at the
normal chromosomal position from which the amplified sequences
are derived (Joos et al, 1993; Lichter et al, 1995). For more accu-
rate analysis ofboth loss and gain ofgenetic material, CGH is then
required. However, CGH involves complex fluorescence ratioing
techniques and expert knowledge of chromosome identification
(Kallioniemi et al, 1993; Houldsworth and Chaganti, 1994; Lichter
et al, 1995). However, both REVISH and CGH would seem to be
ideal methods for detecting genetic changes associated with the
acquisition ofdrug resistance in tumours.
In this study, we have developed a modified REVISH protocol,
which can be applied in laboratories with minimal cytogenetic expe-
rience. This approach was used to investigate the genetics of drug
sensitivity and resistance in a panel ofhuman tumour cell lines.
MATERIALS AND METHODS
Cell lines
The cell lines used in this study (MCF-7, MCF-7ADR, GLC4,
GLC4-ADR and CALU3) have been described previously
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(Bradley et al, 1988; Coutts et al, 1993; Eijdems et al, 1995;
Versantvoort et al, 1995).
Extraction of genomic DNA
High molecular weight genomic DNA for REVISH was extracted
from cell lines using a QIAGEN nucleic acid isolation kit (QIAGEN
Ltd, Dorking, UK) according to manufacturer's protocols.
Locus-specific DNA probes, chromosome paints and
probe labelling
The C-MYC locus-specific probe and whole chromosome paint
probes were purchased from Appligene Oncor (Durham, UK).
ERBB-2 sequences were detected using a mixture oftwo cosmids,
cRCNeul and cRCNeu4 (Murphy et al, 1995a). Topoisomerase II
alpha (TOPOIIa) sequences were detected using cosmid
ICRFC105bO4155 (Murphy et al, 1995b), RARa sequences were
detected using cosmid ICRFCl05FI255, NFl sequences were
detected using cosmid ICRFC105c0861 and NM23 sequences
were detected using cosmid ICRFCl05H12160 developed from
the Imperial Cancer Research Fund Reference Library (Lehrach,
1990). The VHR cosmid was obtained from Dr D Black, Beatson
Institute, Glasgow. Commercial probes were ready labelled with
digoxigenin (Murphy et al, 1995b). Cosmid probes were labelled
with biotin as previously described (Murphy et al., 1995a). All
hybridization conditions were regulated using the Omnislide
modular in situ system (Hybaid, UK). Control hybridizations to
lymphocytes allowed for the characterization of all the probes,
which had hybridization efficiencies from 78% to 96% (McLeod
and Keith, 1996), and for the determination of signal size and
intensity required for quantitative analysis of gene copy number
(Coutts et al, 1993).
Labelling of genomic DNA for REVISH
Complete protocols for the labelling of genomic DNA are available
from the authors on request (WNK, e-mail gpma59@udcf.gla.ac.uk).
Briefly, 1.5 ,ug of genomic DNA was labelled with biotin and the
fragment size range checked (500 bp-2 kb). The labelled probe was
precipitated in thepresence of 150gg ofcot-I DNA and resuspended
in 7 jtl of hybridization mix. The probe was denatured and prean-
nealed at 37°C for 1 h. For dual hybridizations with chromosome
paints, the digoxigenin-labelled paint (7 jil) was also denatured and
preannealed at 37°C for 2.5 h. The probe and paint were then mixed
and added to denatured normal chromosomes and hybridized for2-5
days. In order to control for the REVISH hybridizations, normal
DNA extracted from lymphocytes was used in all experiments. The
labelled normal DNA control reverse paints the chromosomes in an
even fashion, with the expected exception of blocking of repetitive
sequences (owing to inclusion of cot-1 DNA) at, for example,
centromeric sequences. All hybridizations were carried out at least
three times.
Probe detection
Probe detection was described previously using the Hybaid
Omnislide system (Murphy et al, 1995a,b). Fluorescence was
analysed on a Bio-Rad (Richmond, CA, USA) MRC-600 laser scan-
ning confocal microscope equipped with a krypton argon laser.
Original unedited images were stored on optical disks and have been
retained. All processed images were stored as separate files on
optical disks. Optimal colour balance of the pseudocolour images
was achieved using image-processing software (Photomagic,
Micrografx, Arapaho Richardson, Texas, USA). Final figures were
annotated in, and directly printed from, Micrografx Draw
(Micrografx) using a dye sublimation printer (Colour Ease, Kodak,
Harrow, UK).
Fractional length measurements
Hybridization sites were localized by fractional length measure-
ments (Flpter), in which the Flpter is the distance from the probe
location to the end ofthe short arm ofa chromosome dividedby the
total length of the chromosome (Lichter et al, 1990; McLeod and
Keith, 1996). Analysis ofdigitized images forFlpter measurements
was carried out using IPLab Spectrum software with SmartCapture
extensions from Digital Scientific Ltd (Cambridge UK) (McLeod
and Keith, 1996). In addition, GraphPolygon was used to produce
an intensity plot of fluorescence along the profile of the chromo-
some where the width ofthe chromosome was determined in pixels
and the average intensity over the width plotted (McLeod and
Keith, 1996). Published Flpter maps are available from the
Resource for Molecular Cytogenetics at Lawrence Berkeley
National Laboratories and the University of California, San
Francisco, USA (Internet connection, http://rmc-www.lbl.gov/),
and also in BrayWard et al (1996). A minimum of five chromo-
somes were used to determine Flpter positions.
Internet connections
A number of Internet connections were used to access genetic
databases: (1) Resource for Molecular Cytogenetics at Lawrence
Berkeley National Laboratories and the University of California,
San Francisco, USA, Internet connection, http://rmc-www.
lbl.gov/; (2) MRC, Human Genome Mapping Project (HGMP),
Internet connection, http://www.hgmp.mrc.ac.uk/; (3) Online
Mendelian Inheritance in Man (OMIM), Internet connection,
http://www3.ncbi.nlm.nih.gov/Omim/.
RESULTS
Amplification of loci on chromosomes 8 and 17 in
CALU3
In order to develop REVISH, we used the lung adenocarcinoma
cell line CALU3 as a test system and subsequently as a control for
REVISH, as we have considerable experience in using this cell
line to study drug resistance (Coutts et al, 1993). Figure 1 shows
examples of REVISH using test DNA extracted from CALU3
(Figure IA and B) and normal DNA extracted from lymphocytes
(Figure IC and D) in combination with a chromosome 8 paint
probe. The targets for hybridization are normal lymphocyte chro-
mosomes. As can be seen from Figure IC and D, the normal DNA
control reverse paints the chromosomes in an even fashion,
whereas DNA from CALU3 shows intensity changes associated
with copy number alterations to sequences within the CALU3
genome. From the double hybridization of CALU3 DNA and
chromosome 8 paint shown in Figure 1A and B, two regions of
amplification are detected on chromosome 8.
The amplicon on the tip of the q-arm of chromosome 8 was
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Figure 1 Reverse in situ hybridization of normal chromosomes with CALU3 DNA. (A) Image of normal human chromosomes after REVISH with biotin-labelled
genomic DNA from CALU3 (detected with fluorescein isothiocyanate (FITC), pseudocoloured green) and a digoxigenin-labelled chromosome 8 paint
(detected with Cy5, pseudocoloured red). Chromosomes are pseudocoloured blue. (B) Same hybridization as in A showing only the FITC image captured from
the biotin-labelled genomic DNA from CALU3. This image shows the regional changes in sequence copy number more simply than the three-colour merged
image in (A). (C) Image of normal human chromosomes after REVISH with biotin-labelled genomic DNA from normal lymphocytes (detected with FITC,
pseudocoloured green) and a digoxigenin-labelled chromosome 8 paint (detected with Cy5, pseudocoloured red). Chromosomes are pseudocoloured blue.
(D) Same hybridization as in C showing only the FITC image captured from the biotin-labelled genomic DNA from the lymphocytes. Chromosome 8 is marked
in all images
investigated in more detail to understand fully the principle of positions of 0.29 and 0.82 (Figure 2A). Flpter maps for chromo-
how this approach may be used to detect and map chromosomal some 8 published by the Resource for Molecular Cytogenetics at
amplifications. The two chromosome 8 amplicons were localized Lawrence Berkeley National Laboratories and the University of
using fractional length measurements (Flpter) and assigned map California, San Francisco, USA (Internet connection, http://rmc-
British Journal ofCancer (1997) 75(2), 275-282 0 Cancer Research Campaign 1997278 SFHoare etal
U U-Z
U
Figure 2 Amplification of loci on chromosomes 8 and 17 in CALU3. (A) Detail of the FITC image from hybridization of biotin-labelled genomic DNA from CALU3
to normal chromosome 8. The two chromosome 8 amplicons at (1) Flpter=0.29 and (2) Flpter=0.82 are marked. (B) Detail of normal metaphase spread co-
hybridized with genomic DNA from CALU3 (green) and a C-MYC locus-specific probe (red). Chromosomes are shown in blue. A visual representation of the
hybridization site for C-MYC relative to the genomic sequences amplified in CALU3 is shown in C. (C) shows a typical intensity plot for fluorescence along the
profile of chromosome 8 (blue trace), generating a visual representation of the hybridization site for C-MYC (red trace), relative to genomic sequences amplified
in CALU3 (green trace). (D) Hybridization of C-MYC locus-specific probe (green) to metaphase spread chromosomes from the CALU3 cell line (red); showing
amplification of C-MYC. (E) Detail of hybridization of the FITC image from biotin-labelled genomic DNA from CALU3 to normal chromosome 17. Both
chromosome 17 homologues are shown and the amplicon has a Flpter of 0.49. (F) Detail of cosmid probes for chromosome 17 loci to chromosomes prepared
from CALU3. Only the chromosome carrying the amplified loci is shown. Hybridization signal is shown in green, chromosomes in red. The loci for ERBB-2,
TOPOlla, RARax and VHR are amplified. (G) Structure of the chromosome 17 amplicon in CALU3 cells. Only the chromosome (blue) carrying the amplified loci
is shown. (i) Double hybridization of chromosome 17 centromeric sequences (red) and TOPOlla (green), showing linkage of the amplicon to chromosome 17
sequences. (ii) Double hybridization of chromosome 17 centromeric sequences (red) and NF1 (green), showing the position of NF1 close to the centromere as
in normal chromosomes. (iii) Double hybridization of chromosome 17 centromeric sequences (red) and NM23H1 (green), showing the position of NM23H1 close
to the centromere on the abnormal CALU3 chromosome 17. The normal locus order is centromere, NF1, ERBB-2, RARa, TOPOlla, VHR and NM23H1. Thus,
an inversion of chromosome 17 appears to have occurred in CALU3 to bring NM23H1 close to the centromere. (iv) Double hybridization of ERBB-2 (red) and
TOPOIIa (green), showing the physical relationship between the co-amplified genes
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Figure 3 Reverse in situ hybridization of normal chromosomes with genomic DNA from drug-resistant cell lines. (A) Detail of REVISH hybridizations to
normal chromosome 7 using the MCF-7 parental and resistant cell lines. Only the FITC images captured from the biotin-labelled genomic DNA from the lines is
shown. (B) Detail of REVISH hybridizations to normal chromosome 16 using the GLC4 parental and resistant cell lines. Only the FITC images captured from the
biotin-labelled genomic DNA from the lines is shown. (C) Detail of REVISH hybridizations to normal chromosome 1 using the GLC4 parental and resistant cell
lines. Images of normal human chromosome 1 after REVISH hybridization with biotin-labelled genomic DNA from the GLC4 parental and resistant cell lines
(detected with FITC, pseudocoloured green). Chromosomes are pseudocoloured red. The amplification at the telomeric region of chromosome 1q common to
both the parental and resistant lines can be seen, as can the amplification unique to the resistant line. Thresholding was used to observe only the peak
fluorescence intensities and these images are adjacent to the original images. The p-arm of each chromosome is marked with an arrow
www.lbl.gov/), show the C-MYC oncogene to have a Flpter of
0.84 and it may therefore reside within the amplicon. This was
analysed in two ways. Firstly, the physical relationship between
the C-MYC locus and the amplicon was addressed by co-
hybridizing a C-MYC probe with the genomic DNA from CALU3
in a modified REVISH experiment. As shown in Figure 2B and C,
the C-MYC locus maps to the edge ofthe amplicon and may there-
fore define a marker close to the border of this rather extensive
amplicon. Secondly, in order to test directly whether the C-MYC
gene is amplified in CALU3, the C-MYC probe was hybridized to
chromosomes prepared from CALU3 as shown in Figure 2D.
Figure 2D shows that C-MYC is indeed amplified in CALU3 with
copies distributed over a number ofchromosomal sites, and so lies
within the border of the amplicon (Figure 2C). However, it is
worth noting that the amplicon extends over an area greater than
just C-MYC (Figure 2B and 2C), and therefore numerous other
loci are likely to be contained within this amplicon, a conclusion
which would not have been reached had the cell line been analysed
for C-MYC amplification by FISH alone. These experiments show
the value and robust nature ofusing REVISH in combination with
Flpter mapping and FISH to identify a previously uncharacterized
amplicon and provide a strategy for analysis.
We have previously shown CALU3 to have co-amplification of
the topoisomerase Ila (TOPOIIx) locus with other markers on
chromosome 17, including ERBB-2 and RARax (Keith et al, 1992;
Coutts et al, 1993), with the ERBB-2 locus amplified around 30-
fold (Keith et al, 1992). We therefore compared the REVISH
analysis with standard FISH to evaluate whether REVISH was
capable of detecting the chromosome 17 amplicon in CALU3.
Figure 2E shows detail of two chromosome 17 homologues after
REVISH with CALU3 DNA, which clearly shows evidence of a
site ofamplification. The chromosome 17 amplicon was localized
using Flpter and assigned a map position of 0.49. Flpter maps
for chromosome 17 published by the Resource for Molecular
Cytogenetics at Lawrence Berkeley National Laboratories and
the University of California, San Francisco, USA, show the
ERBB-2 oncogene to have a Flpter of 0.49, thus positioning the
REVISH amplicon at a site consistent with our knowledge of gene
amplification on chromosome 17 in CALU3 (Keith et al, 1992;
Coutts et al, 1993).
However, in order to investigate further the relationship
between the fluorescence signal generated by REVISH and the
relative levels of amplification of specific loci within this region,
metaphase preparations from the CALU3 cell line were analysed
by FISH. Six cosmid probes localizing to chromosome 17q were
used (NFl, ERBB-2, TOPOIla, RARa, VHR and NM23H1)
(Albertsen et al, 1994; Jones et al, 1994; Neuhausen et al, 1994).
Figure 2F shows examples of hybridizations to a chromosome
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carrying co-amplification ofERBB-2, TOPOIIx, RARax and VHR
as a homogeneously staining region. The loci, NFl and NM23H1,
which reside either side of ERBB-2, TOPOIIoc, RARax and VHR
on chromosome 17q, are present as single copies and therefore
define the limits of the amplicon. Interestingly, the amplified loci
show variation in levels of amplification with ERBB-2 amplified
to the greatest level followed by TOPOlIIc. RARct and VHR are
present as two small blocks of amplification (Figure 2F). Double
hybridization experiments with these probes showed all the above
loci to be still physically linked within the chromosome 17
carrying the amplicon (Figure 2G) and that there appears to be an
inversion of the amplified region within chromosome 17 as
defined by the hybridization position of the NM23H1 probe rela-
tive to the normal map positions of the chromosome 17 genes
analysed. This pattern of amplification is consistent with unequal
sister chromatid exchange mechanism of amplification (Stark
1993). Thus, this amplicon is derived from a region over 3
megabases in size, which on a normal chromosome encompasses
the breast cancer susceptibility locus, BRCA1 (Albertsen et al,
1994; Jones et al, 1994; Neuhausen et al, 1994). The hybridization
signal generated by REVISH shown in Figure 2E is therefore a
product of a large amplicon originating from a region encom-
passing at least 3 megabases, yet the signal size and intensity are
similar to that of a cosmid or P1 genomic probe used for standard
FISH. This suggests that only the most highly amplified sequences
are detected by the REVISH approach and that the true extent of
the amplicon may only be detected by FISH using locus-specific
cosmid probes.
Amplification of loci in drug-resistant cell lines
A major objective of this study was to ascertain whether REVISH
could detect chromosomal changes present between closely related
pairs of cell lines selected for drug resistance from a sensitive
parental line. Two paired lines were analysed, the breast line MCF-
7 and its doxorubicin-resistant derivative, MCF-7ADR, and the
small-cell lung cancer cell line GLC4 and its doxorubicin deriva-
tive, GLC4-ADR. REVISH analysis of the MCF-7 and MCF-
7ADR lines identified a number of sites of amplification common
to both lines and a site of amplification on chromosome 7q found
only in the doxorubicin-resistant line. Figure 3 shows examples of
the chromosome 7 REVISH signals for DNA extracted from MCF-
7 and MCF-7ADR lines. The hybridization pattern for the parental
line shows an imbalance in sequence between the p and q arms of
chromosome 7, which is retained in the resistant line (Figure 3).
However, the resistant line shows a very specific amplification
mapping to 7q with a Flpter of0.57. This localization is consistent
with the map position of the multidrug resistance locus, MDR1, at
7q21.1, which is known to be amplified in the MCF-7 doxorubicin-
resistant line and contributes to the drug-resistant phenotype of the
line (Bradley et al, 1988).
A second doxorubicin-resistant cell line, GLC4-ADR, and its
parental line were analysed by REVISH. As with the MCF-7 lines,
REVISH identified a number of sites of amplification common to
both the GLC4 and GLC4-ADR lines. However, two sites of
amplification were present only in the GLC4-ADR line (Figure 3).
The first amplicon mapped to chromosome 16p with a Flpter of
0.22. This localization is consistent with the map position of the
locus coding for the multidrug resistance protein, MRP, at 16pl3,
which is known to be amplified in the GLC4 doxorubicin-resistant
line and contributes to the drug-resistant phenotype of the line
(Eijdems et al, 1995). Interestingly, a second amplicon mapped to
chromosome lq with a Flpter of 0.67. Figure 3 shows detail of the
REVISH hybridization to chromosome 1 in both the GLC4 and the
GLC4-ADR lines. Both lines have an amplicon mapping to the
distal telomeric region of chromosome 1 with the amplicon
specific to the resistant line present below the centromere and
heterochromatic region of chromosome 1. The amplicon at Flpter
= 0.67 in the resistant line has not been described previously and
there is no clear candidate locus as yet mapped to this region that
could participate in the resistance phenotype. Therefore, it is now
important to identify the specific sequences present in this
amplicon by a combination of approaches, including those
described above, and test whether they do indeed contribute to the
resistance phenotype.
DISCUSSION
This study shows the application ofreverse in situ hybridization to
detect, map and characterize genetic changes associated with the
sensitivity of cell lines to anti-cancer agents. In order to use
REVISH for this purpose, a number of steps are carried out:
1 An initial reverse in situ hybridization is carried out using
genomic DNA extracted from the test cell lines and compared
with normal DNA controls (see Figure 1). A visual analysis of
the resultant hybridization allows the key chromosomes with
regional amplifications to be identified by their size and
centromere position.
2 Confirmation of chromosomal identification is obtained by
co-hybridizing the test cell line DNA with a whole chromo-
some paint and visualizing the two probes with different
fluorochromes (see Figure 1). We have found this to be an
important modification to standard REVISH protocols as it
allows unambiguous chromosome identification in laboratories
without cytogenetic experience.
3 Precise localization of the amplified sequences is carried out
using fractional length measurements (Flpter).
4 Using the reference maps for Flpter measurements available
through the Internet and also in BrayWard et al (1996),
candidate loci or specific markers for the region of interest
are identified.
5 Detailed genetic analysis ofcandidate loci are carried out by,
for example, FISH (see Figure 2 for an example).
6 Using the information derived above, traditional positional
cloning strategies can then be applied to the newly identified
region of interest.
Initially, we applied the REVISH strategy to the CALU3 cell
line as we have a considerable amount of knowledge about the
genetic changes to the TOPOIIa locus in this line, and this there-
fore allowed us to determine how robust the above strategy for
REVISH was (Coutts et al, 1993). Following the above schedule
for REVISH analysis, two major sites ofamplification were chosen
for study in detail, the first on chromosome 8q and the second on
chromosome 17q. By REVISH, the two amplicons had different
appearances, with the chromosome 8q amplicon starting at a Flpter
of 0.82 and extending to the distal tip of the chromosome, thus
covering some 18% ofthe total length ofthe chromosome (Figures
1 and 2A, B and C). A particularly informative experiment was to
co-localize the C-MYC probe to the chromosome 8 amplicon by
co-hybridization experiments (Figure 2B and C). Thus, although
the C-MYC gene is amplified in CALU3 (Figure 2D), it is at the
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boundary ofthe amplicon (Figure 2Band C) with potentially a large
number of other loci co-amplified. It is, therefore, not clear what
the selective locus for this amplicon is, a conclusion which would
not necessarily have been reached by the FISH studies with C-
MYC alone on CALU3. By comparison, the chromosome 17q
amplicon detected by REVISH had the appearance of a hybridiza-
tion signal from a cosmid probe, yet contains at least four genes
and originates from a region of over several megabases of DNA
(Figure 2E and F) (Albertsen et al, 1994; Jones et al, 1994;
Neuhausen et al, 1994). Therefore, the combined REVISH and
FISH analysis of the chromosome 17 amplicon suggests that only
highly amplified sequences are detected by REVISH.
Our conclusions from these initial studies on CALU3 are that it
is a relatively simple procedure to integrate the Flpter data gener-
ated by REVISH in our laboratory with the published Flpter maps
to localize accurately and then investigate amplified regions of the
genome. However, once the general characteristics of an amplicon
have been described in terms of position and extent, fine detail
analysis of the relative genetic composition of an amplicon is best
carried out using locus-specific probes. In addition, REVISH is
capable ofcharacterizing an amplification, including the TOPOIIlc
locus, which occurs in breast tumour biopsies and which can affect
its expression (Keith et al, 1993; Murphy et al, 1995a).
It is apparent from the REVISH studies shown here, as well as
published data from a number of others, that the overall picture
of genetic changes detected by REVISH in any one sample
is complex (Joos et al, 1993; Houldsworth and Chaganti, 1994;
Kallioniemi et al, 1993; Van Ommen et al, 1995). It is, therefore,
important when investigating acquired drug resistance that changes
specifically associated with the drug-resistant test sample or cell
line can be identified among the genetic alterations common to both
the parental and resistant lines. In order to address this question, we
used two pairs of parental and drug-resistant cell lines. The MCF-
7ADR doxorubicin-resistant cell line is known to have amplifica-
tion ofthe MDR1 gene (Bradley et al, 1988), and this amplification
is detected and mapped by REVISH (Figure 3). This amplification
on chromosome 7 was identified among abackground ofamplifica-
tions, including chromosomes 17, 3 and 20 common to both the
parental and resistant MCF-7 cell lines (data not shown). Similarly,
detection and mapping of the MRP amplification on chromosome
16 in the doxorubicin-resistant line, GLC4-ADR, was possible
among a background of amplifications, including chromosomes 1
and 8 common to both the parental and resistant GLC4 cell lines.
Therefore, by using genomic DNA extracted from the cell lines as a
complex probe, drug resistance-specific changes can be detected
without the use ofcloned genes or specialized genetic reagents.
Interestingly, REVISH also detected and mapped a second
unique amplification in the GLC4-ADR line to chromosome 1q
(Flpter=0.67). Resistance to doxorubicin in the GLC4-ADR line is
known to be multifactorial and not all the contributing elements
have been elucidated. It is therefore possible that the amplification
of loci at chromosome 1, Flpter=0.67, may contribute to the resis-
tance. From the published information on loci on chromosome 1,
there are no obvious candidate loci that can be tested. However,
the mapping of this amplicon affords an entry point for cloning
strategies. In addition, it is now possible to screen other drug-resis-
tant cell lines by REVISH to ascertain the frequency of this alter-
ation without having to derive locus-specific probes. This latter
approach may also help prove indirectly whether the chromosome
1 amplicon is relevant to the resistance phenotype or a single
chance event unrelated to resistance in the GLC4-ADR line.
In conclusion, we have shown that REVISH is a useful approach
to study genetic changes associated with drug resistance. A major
contributing factor to the success of this approach is ease of inte-
gration ofthe data produced in our laboratory with published refer-
ence maps and genome databases, thus allowing us to access both
information and potential reagents. Although REVISH is sensitive
enough to detect gene amplification, this approach would be
strengthened considerably by the application of comparative
genomic hybridization to detect more subtle losses and gains in a
quantitative fashion. However, both REVISH and CGH are valu-
able genetic methodologies with which to study drug resistance
and are ideally suited to the analysis ofarchive tumour biopsies, an
important consideration for future studies (Speicher et al, 1993;
Isola et al, 1994; Kallioniemi et al, 1994; Ried et al, 1995).
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